EGFR and adenocarcinoma in situ: Although a few reports mentioned genetic mutations in cut-end second tumors, Isaka and colleagues6 summarized 6 cases of cut-end second tumors after resection of adenocarcinoma in situ and mentioned the epidermal growth factor receptor (EGFR) expression status and treatment methods for both primary and secondary tumors.